Watch INKT. Know when insiders buy.
One email the day a filing lands. Free.
INKT
MiNK Therapeutics, Inc.
11.71
+0.12 +1.04%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $59.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$11.4MNET CASH —52W 8.56 – 16.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.2M | −$3.1M | — | -0.62 | −$2.1M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2.9M | −$2.7M | — | -0.57 | −$1.7M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.7M | −$2.6M | — | -0.54 | −$2.1M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$3.2M | −$2.9M | — | -0.65 | −$941K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.1M | −$4.2M | — | -1.06 | −$1.6M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$2.7M | −$2.8M | — | -0.70 | −$1.3M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.5M | −$2.5M | — | -0.62 | −$1.7M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$1.9M | −$1.8M | — | -0.46 | −$3M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$3.1M | −$2.7M | — | -0.73 | −$2.3M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3.8M | −$3.8M | — | -1.10 | −$2.5M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.5M | −$5.5M | — | -6.04 | −$3M | $0 | −$3M | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$5.2M | −$5.1M | — | -0.15 | −$4.2M | $23K | −$4.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$12.6M | −$12.5M | — | -2.93 | −$5.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$11.3M | −$10.8M | — | -2.86 | −$9.6M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$22.9M | −$22.5M | — | -6.54 | −$15.8M | $74K | −$15.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$30.9M | −$28M | — | -0.83 | −$18.9M | $250K | −$19.1M | — | — |
| FY2021 · to Dec 31 | — | — | −$28.4M | −$30.2M | — | -1.16 | −$12.8M | $249K | −$13.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$14.6M | −$16.2M | — | -0.67 | −$8.3M | $95K | −$8.4M | — | — |
Every number comes from MiNK Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.